Recent Updates
Recently added Catalysts
PTN

PRESENTATION ON SEPTEMBER 14, 2010

Tuesday, September 14, 2010 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PRESENTATION ON SEPTEMBER 14, 2010

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~4 mo
High dilution risk
Lead asset
Bremelanotide
Phase 3 · Hypoactive Sexual Desire Disorder

Full Press Release Details

PRESENTATION ON SEPTEMBER 14, 2010.
ShareAdd on Google
Tags: PTN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Sep 14, 2010

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~4 mo
High dilution risk
Lead asset
BremelanotidePhase 3
Hypoactive Sexual Desire Disorder →